Антиатерогенные эффекты симвастатина, эзетимиба и их комбинации натощак и после пищевой жировой нагрузки у больных коронарной болезнью сердца с гиперлипидемией
Диссертация
ПРАКТИЧЕСКАЯ ЗНА ЧИМОСТЬ Доказана эффективность нового генерического препарата симвастатина — симло в коррекции ГЛП у больных КБС и его безопасность. Полученные в исследовании данные о гиполипидемических и других антиатерогенных эффектах эзетимиба и симвастатина — симло продемонстрировали их высокую эффективность в коррекции дислипидемии как натощак, так и в постпрандиальный период, более… Читать ещё >
Список литературы
- Агеев Ф.Т. Что ограничивает применение статинов в повседневной амбулаторной практике? Сердце, 2004- 3, 3 (15), 146 9.
- Аронов Д.М. Лечение и профилактика атеросклероза. М, Триада-Х. 2000. 411 стр.
- Аронов Д.М. Симвастатин. Триада-Х. М., 2002, 80.
- Аронов Д.М., Бубнова М. Г., Перова Н. В. и др. Физические нагрузки и атеросклероз: проатерогенное влияние статических нагрузок высокой и умеренной интенсивности на липид-транспортную систему крови. Кардиология, 2003- 2: 35 9.
- Бойцов С.А., Явелов И. С., Шальнова С. А. с соавт. Национальный регистр острого коронарного синдрома в России: современное состояние и перспективы. Кардиоваскулярная терапия и профилактика. 2007- 6(4), 115 — 20.
- Бубнова М.Г., Аронов Д. М., Перова Н. В. и др. Никотиновая кислота (пролонгированная форма эндурацин) повышает толерантность липид-транспортной системы к атерогенному воздействию пищевых жиров. Клин фармак тер, 2002- 11(4): 26 30.
- Бубнова М.Г., Аронов' Д.М., Перова Н. В. и др. Физические нагрузки и атеросклероз: динамические физические нагрузки высокой интенсивности как фактор, индуцирующий экзогенную дислипидемию. Кардиология, 2003−3:37−43.
- Бубнова М.Г., Аронов Д. М., Перова Н. В., Мазаев В. П. Связь уровня липемии после жировой нагрузки с выраженностью атеросклероза коронарных артерий. Тер. Архив. 2004. 76 (6): 62 — 7.
- Бубнова М.Г., Оганов Р. Г. Нарушенная толерантность к пищевым жирам и ее значение в атеротромбогенезе. Тер. Архив. 2004, 76(1): 73 8.
- Бубнова М.Г., Перова Н. В., Олферьев А. М., Красницкий В. Б., Лобикова C.B. Варианты чувствительности больных коронарной болезнью сердца к гиполипидемическому действию симвастатина. Кардиоваскулярная терапия и профилактика, 2002, 1- 3: 55 62.
- Герасимова E.H., Перова Н. В. Саморегуляция функционального состояния липопротеидов высокой плотности и нарушение ее при гипоальфахолестеринемии. Вопросы мед. химии, 1985, 1, 32−40.
- Грацианский H.A. Эзетимиб перспективный компонент комбинированной гиполипидемической терапии. Фарматека., 2005.
- Затейщиков Д.А. Интенсивная гиполипидемическая терапия: современные возможности комбинирования гиполипидемических препаратов. Фарматека, 2004, 19/20: 25 32.
- Кухарчук В.В., Бубнова М. Г., Кательницкая Л. И. с соавт. Эффективность и безопасность симвастатина у пациентов с гипрехолестеринемией (результаты многоцентрового клинического исследования). Кардиология. 2003, 5:42−7.
- Лякишев A.A. Эзетимиб: новый гиполипидемический препарат с уникальными свойствами. Фарматека 2005- 6: 46−50.
- Марцевич С.Ю., Перова Н. В., Кутишенко Н. П. с соавт. Открытое клиническое исследование эффективности и безопасности нового дженерика симвастатина симвостола. Клиническая фармакология и терапия. 2005, 14(3).
- Медико-демографические показатели Российской Федерации в 2005 г. Статистические материалы. Млсква, Минздравсоцразвития. 2006, 176 с.
- Метелица В.И. Справочник по клинической фармакологии сердечнососудистых лекарственных средств. М., Бином СПб., Невский диалект, 2002, 926.
- Оганов Р.Г., Масленникова Г .Я. Развитие профилактической кардиологии в России. Кардиоваскулярная терапия и профилактика, 2004- 3(3), 10−4.
- Перова Н.В. Аполипопротеины при дислипопротеидемиях и атеросклерозе. Дисс. доктора мед.наук. М. — 1982.
- Перова Н.В. Расширение механизмов действия медикаментозных средств, нормализующих уровень холестерина. Атмосфера кардиология. 2005- 2: 9 — 16.
- Перова Н.В., Бубнова М. Г., Аронов Д. М. и др. Влияние ловастатина на концентрацию липидов и аполипопротеинов сыворотки крови после алиментарной жировой нагрузки у больных ишемической болезнью сердца. Кардиология, 1993- 4: 8 -10.
- Перова Н.В., Марцевич С. Ю., Кутешенко Н. П. с соавт. Клиническое исследование влияния на гиперлипидемию, фосфолипидный состав липопротеидов высокой плотности и параметры безопасности генерика симвастатина симвастола. Атмосфера кардиология, 2004- 5,2 -7.
- Томпсон Г. Р. Руководство по гиперлипидемии. М, MSD, 1991, 255.
- Фомичева О.А., Демидова А. К., Сорокин Е. В. с соавт. Влияние трехмесячного лечения симвастатином на показатели липидного обмена и С-реактивный белок у больных стабильной ИБС. РМЖ, 2003, 11- 19: 4- 10.
- Чазов Е.И. Будущее кардиологии в свете успехов в медицинской науке. Кардиоваскулярная терапия и профилактика, 2004- 3(3), 6 -9.
- Шевченко О.П., Шевченко, А .О. Статины ингибиторы ГМГ-КоА-редуктазы. М., Реафарм, 2003, 112.
- Abdel-Maksoud MF, Hokanson JE. The complex role of triglyceride in cardiovascular disease. Semin Vase Med. 2002- 2(3): 325 33.
- Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in clinical practice: a postmarketing analysis. Circulation. 2005- 111.
- Altmann SW, Davis HR J, Zhu LJ et al. Niemann-Pick CI Like 1 protein is critical for intestinal cholesterol absorption. Science 2004- 303: 1201−4.
- American Heart Association. AHA dietary guidelines: revision 2000. Circulation. 2000, 102: 2284 99.
- Armitage J, Collins R, MRSBHF Heart Protection Study Collaborative Group, in: «State of Heart Protection Study. New clinical developments in the treatment of coronary heart disease», February, 2002, Seville, Spain, MSD.
- Assman G, Schkiewer H, Schmitz G et al. Quantification of HDL cholesterol by precipitation with phosphotungstic acid/MgCl 2. Clin Chem. 1983,29(12): 2026 -30.
- Assman G. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996, 124- 11−20.
- Ballantune FC, Wiliamson J, Shapiro D. Estimation of apoprotein B in man by immunonephelometry. Clin Chem, 1978 — 24: 788 92.
- Ballantyne CM, Houri J, Notarbartolo A, et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolaemia: a prospective, randomized, double-blind trial. Circulation 2003−107:2409−15.
- Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004- 58: 653- 8.
- Barbir M, Wile D, Trayner I, et al. High prevalence of hypertriglyceridaemia and abnormalities in coronary artery disease. Br Heart J, 1988- 60: 397 403.
- Barter PhJ, Rye KA. Molecular mechanisms of reverse cholesterol transport. Curr opion in lipidol. 1996- 7, 82 7.
- Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolaemia: pooled analysis of two phase II studies. Clin Ther, 2001- 23: 1209 30.
- Betteridge DJ, Morrell JM. Clinicians guide to lipids and coronary heart disease. Arnold, a member of the Hodder Headline Group- second edition.2003, 368.
- Bihari-Varga M, Gruber E, Rothender M et al. Interaction of lipoprotein (a) and low density lipoprotein with glycosoaminoglycans from human aorta. Aterosclerosis, 1988, 8: 851 -7.
- Bjerre LM., LeLorier J. Do statins cause cancer? A metaanalisis of large randomized clinical trails. A J Med, 2001- 110:716 23.
- Blais L, Desgagne A, LeLorier J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. Arch Intern Med., 2000- 160: 2363 -8.
- Brohet C, Banai S, Alings AM, et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin. 2005- 21(4): 571 8.
- Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med 1991- 324(16): 1133 5.
- Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990- 323: 1289 98.
- Brown MS, Goldstein JI. Teaching old dogmas new tricks. Nature, 1987- 330: 113−4.
- Buchwald H. et al. and POSCH Group «Effect of partial ideal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia». New Engl. Journal of Medicine, 1990, 323, 946 55.
- Bucolo G, David H. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem. 1973, 19: 476 82.
- Carlson LA, Bottiger LE. Risk factors for ishaemic heart disease in men and women. Results of the 19-year follow-up of the Stockholm Prospective Study. Act Med Scand, 1985−218:207−11.
- Castelli WP, Garrison RJ, Wilson PWF et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. JAMA, 1986, 256: 2835 38.
- Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J, 1986- 112: 432−37.
- Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a metaanalysis of pooled data from 14 clinical trials. Curr Med Res Opin. 2005- 21(7): 1123−30.
- Catapano AL, Davidson MH, Balantyne CM et al. Lipid altering-efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006- 20(10): 2041 53.
- Corti R., Fayad Z, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation, 2002, 106(11): 1308 -9.
- Daskalopoulou SS, Mikhalidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol syntesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin. 2006- 22(3): 511 28.
- Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolaemia. J Am Coll Cardiol 2002−40(12): 2125−34.
- Davidson MH. Clinical significance of statin pleiotropic effects. Hypothesis versus evidence. Circulation 2005- 111: 2280−1.
- Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaque: role of extracellular lipid, macrophage and smooth muscle cell content. Br. Heart J., 1993, 69, 377−81.
- Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: A look back and a look a head. Can.J.Cardiol. 1992, 8,8, 843 64.
- Demel RA, Jansen JW, Dijek PWM et al. The preferential interaction of cholesterol with different classes of phospholipids. Biochem. Biophys. Act, 1977, v. 465- 1−10.
- Dimitroulakos J, Nohynek D, Backway KL et al. Increased sensitivity of acute myeloid leukemias to lovastatininduced apoptosis: a potential therapeutic approach. Blood, 1999- 93: 1308 -18.
- Durrington PN, Ishola M, Hunt L et al. Apolipoproteins (a), AI and B and parental history in men with early onset ischemic heart disease. Lancet, 1988, 8: 1070−3.
- Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984. 25- 1017 -58.
- Eisenberg S, Olivecrona T. Very low density lipoprotein, fate of phospholipids, cholesterol and apolipoprotein C during lipolysis in vitro. J Lipid. Res., 1989- 20 (5) — 614−23.
- Erkelens DW. Man is a postprandial subject and postprandial triglyceride-rich lipoprotein remnants are atherogenic. Nutr Metab Cardiovasc Dis, 1993- 3: 99 -101.
- EuroAspire I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EuroAspire I and II Group in nine countries. Lancet, 2001- 357: 995- 1001.
- EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries, Principal results from EUROASPIRE II Euro Heart Survey Program. Eur Heart J, 2001- 22(7): 554 -72.
- EUROASPIRE Study Group. A European society of cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J, 1997- 18: 1569.
- Evans M, Roberts A, Davies S, et al. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs. 2004- 64(11): 1181 -96.
- Ezzet F, Wexler D, Statkevich P, et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol, 2001- 41(9):943 -9.
- Faergeman O. Evolution of statin therapy: an ongoing story. Eur Heart J. 2004- 6 (Suppl A): 3 -7.
- Farmer GA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug saf. 2000- 23: 197−213.
- Farnier M, Volpe M, Massaad R, et al. Effect of co-administering ezetimibe with on-going Simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol. 2005- 102(2): 327−32.
- Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 1995,36,211 -28.
- Friedewald WT, Levy RI, Fredricson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499 502.
- Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994: 90:2126−46.
- Garcia-Calvo M, Lisnock J-M, Bull HG. et al. The target of ezetimibe is Niemann-Pick Cl-Like 1 (NPC1L1). PNAS 2005−102: 8132−7.
- Goldberg F.C. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controled trial. Mayo Clin Proc. 2004- 79: 620 9.
- Gotto AJ. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol, 1998- Nov 5- 82(9A): 22 25.
- Gotto AM, Patsch JR, Yamamoto A. Postprandial hyperlipidemia. Am J Cardiol. 1991- 68: 11−2.
- Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004- 110: 227 -39.
- Guallar E, Goodman SN. Statins and cancer: a case of meta-uncertainty. Am J Med, 2001- 100: 738−40.
- Heart Protection Study Collaborative Group MRSBHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancent, 2002, 360: 7 22.
- Heart Protection Study Collaborative Group. Tne effects of cholesterol liwering with simvastatin on cause-specific mortality and on cancer incidence in 20 536 high-risk people: a randomized placebo-controled trial. BMC Med, 2005−16(3):6.
- Hegele RA., Guy J, Ban MR, Wang J. NPC1L1 haplotype associated with interindividual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. 2005- 4: 16.
- Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996- 3(2): 213−9.
- Horne BD., Muhlestein JB, Carlguist JE et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am. Coll. Cardiol. 2000- 36(6): 1774 80.
- International Committee for the Evaluation of Hypertriglyceridemia as a Vascular Risk Factor. Hypertriglyceridemias: Risk and Management. G Lorenzini Med Found. Milan, Italy, Houston, USA, 1 20.
- Itakura H, Kita T, Mabuchi H, et al. Primary prevention of coronary events with simvastatin in 47 294 Japanese hypercholesterolemic patients results of J-LIT Study. XIV Intern. Simp. «Drugs Effecting Lipid Metabolism», New York, 2001, 117 (abstract).
- J Alan Herd et al. Effects of Fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study LCAS. Am J Cardiol. 1997- 80: 278 86.
- Jensen LO, Thayssen P, Pedersen KE, et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation, 2004- 110: 265 70.
- Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease six year follow-up experience. The Framingham Study. Ann Inten Med 1961- 55: 33−50.
- Karpe F, Steiner G, Uffelman K et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis, 1994- 106: 83 97.
- Kerzner B, Corbelli J, Sharp S, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe co-administered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003- 91: 418−24.
- Kluft C, De Maat MPM, Leuven JA, et al. Statins and C-reactive protein. Lancet, 1999- 353: 1274−5.
- Knoop RH, Gitter H, Truitt T, et al. Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolaemia. Eur Heart J, 2003- 24(8): 729 41.
- Kosoglou T, Statkevich P, Johnson-Levonas AO et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005- 44: 467−94.
- Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004- 20: 1185−95.
- Kunz F, Pechlaner C, Erhart F, et al. HDL and plasma phospholipids in coronary artery disease. Artherioscler. Tromb, 1994- 14: 1146 1150.
- La Rosa JC, Grundy SH, Waters DD, et al. Intensive lipid-lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005, 352: 1425−35.
- Lammert F., Wang D.Q. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology 2005- 129: 718−34.
- Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation2005- 111: 2356−63.
- Laufs U, la Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 1998, 97: 1125 35.
- Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest. 1972, 29: 21 -37.
- Lee RT, Libby P. The unstable atheroma. Atheroscler. Thromb. Vase. Biol., 1997, 17, 1859−67.
- Levy RI. High density lipoproteins. 1978. 13- 911 13.
- Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. Reduction in incidence of coronary heart disease. JAMA, 1984- 251:351 -64.
- Lopes-Virella MFL, Virella G, Evans G, et al. Immunonephelomeric assay of human apolipoprotein AI. Clin Chem, 1980, 26: 1205 -8.
- Loree HM, Tobias BJ, Gibson LJ et al. Mechanical properties of model atherosclerotic lesion lipid pools. Atheroscler Thromb. 1994- 14: 230 4.
- MAAS investigators. «Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS)». Lancet, 1994, 344, 633 38.
- Macaulay RJ, Wang W, Dimitroulakos J. et al. Lovastatin induced apoptosis of human medulloblastoma cell lines in vitro. J Neurooncol, 1999- 42: 1−11.
- Mamo JCL, Yu KCW, Elsegood CL et al. Is atherosclerosis exclusively a postprandial phenomenon? Clin Exp Pharmacop Physiol, 1997, 24: 288 93.
- Mamo JCL. Atherosclerosis as a postprandial disease. Endocr Metabol, 1995, 229 -44.
- Melani L, Mills R, Hassman D, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe co-administered with pravastatin in patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Eur Heart J 2003- 24: 717−28.
- Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005- 21: 959−69.
- Miller M, Jialai I. Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. Am J Cardiol, 2002- 89: 468−9.
- Molgaard J, Warjekstam ES, Olsson AG. Efficacy and safety of simvastatin for high-risk hypercholesterolemia. Am.J.Cardiol. 1999- 83(7): 1043 8.
- Nacashima Y, Toyokawa N, Tanaka S, et al. Simvastatin increases plasma NO-2 and NO-3 levels in patients with hypercholesterolemia. Atherosclerosis, 1996- 127: 43−7.
- Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 1992- 152: 1490−500.
- Nissen SE, Tuzcu EM, Shoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on procession of coronary atherosclerosis/ A randomized controlled trial. JAMA 2004- 291:1071 80.
- Nissen SE, Nicholls SJ, Sipahi I, et al, for the ASTEROID Investigators. Effect of Very High-Intensive Statin Therapy on Regression of Coronary Atherosclerosis. The ASTEROID Trial. JAMA, 2006- 295.
- O’Driscoll G, Green D, Tylor R. Simvastatin an HMG-CoA reductase inhibitors, improves endothelial function within 1 month. Circulation, 1997- 95: 1126−31.
- Oliver MF, Davies MJ. The atheromatous lipid core. Eur Heart J., 1998- 19: 16 -8.
- Ory DS. Nuclear Receptor Signaling in the Control of Cholesterol Homeostasis. Have the Orphans Found a Home? Circ Res 2004- 95: 660−70.
- Ose L., Bays HE, Eraser N, et al. EzetimibeSimvastatin Therapy is More Effective Than Simvastatin Alon at Reducing Remnant-Like Particle Cholesterol. MSD, Schering-Plough. 2006.
- Patch JR, Miesenbock G, Hopferwieser T et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arteriose Thromb, 1992,12: 1336 45.
- Patsch JR, Karlin JB, Scolt LW, et al. Inverse relationship between levels of high density lipoprotein and magnitude of postprandial lipemia. Proc Nat Acad Sei USA, 1983- 80: 1449−53.
- Pearson T. EASE: Ezetimibe Add-on to Statin for Effectiveness Trial. American College of Cardiology. Annual Scientific Session, 2004.
- Pedersen TP, Jahnsen KE, Vatn S, et al. Benefits of lipid-lowering intervention in high-risk patients- the lipid intervention strategies for coronary patients study. Clinical Therapeutiec, 2000, 22, 8, 949 60.
- Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother, 2004- 5(12): 2583−96.
- Recommendations of International Federation of Clinical Chemistry, Scientific Committee. J Clin Chem Clin Biochem, 1980, 18: 521−34.
- Ridcer PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. Curr atheroscler Rep. 2006 — 8 (1): 8 9.
- Ridker PM, Rifai N, Pfeffer MA, et al. for the Cholesterol and Recurrent Events (CARE) Investigators. Lon-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation, 1999- 100: 230−5.
- Roberts W. The rule of 5 and of 7 in lipid-lowering by statin drugs. Am J Cardiol., 1997- 80: 106 -7.
- Roeschlau P, Berndt E, Gruber W. Enzymatische bestimmung des gesamtcholestekines in serum. Z Klin Chem Clin Biochem. 1974, 12: 226 — 9.
- Sager P.T., Capece R., Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005- 179: 361−7.
- Scandinavian Simvastatin Survival Study Group. «Randomised trial of cholesterol lowering in 4444 patitnts with coronary heart disease the Scandinavian Simvastatin Survival Study (4S)». Lancet, 1994, 344, 1383 89.
- Shechter M, Sharir M, Labrador MJP, et al. Improvement in endothelium-dependent brachial artery flow-mediated vasodilatation with low density lipoprotein cholesterol levels < 100 mg/dl. Am J Cardiol, 2000, 86: 1256 58.
- Snyder DW, Crafford WA, Glashow JL, et al. Lysophosphoglycerides in ischemic myocardium effluents and potentiality of their arrhythmogenic effects. Am J Physiol Heart Circ Physiol. 1981- 241: 700 7.
- Sobel BE, Corr PB. Biochemical mechanisms, potentially responsible for lethal arrhythmias induced by ischemia: the lysolipid hypotesis. Adv Cardiol, 1979- 26: 76−85.
- Stampfer MJ, Krauss RM, Blanche PJ et al. Prospective Study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA, 1996- 276: 882 8.
- Stein E, Evan M. Efficacy and safety of simvastatin 80mg/day in hypercholesterolemic patients. Am J Cardiol. 1998- 82: 311 6.
- Steinberg D. Oxidative modification of LDL and atherogenesis. Circulatiion, 1997- 95: 1062−71.
- Steinhagen-Thiessen E et al for the Simvastatin Pravastatin European Study Group. Comparative efficacy and tolerability of 5 and 10 mg Simvastatin and 10mg Pravastatin in moderate primary hypercholesterolemia. Cardiol, 1994- 85: 244−54.
- St-Pierre AC, Cantin B, Dagenais GR, et al. Apolipoprotein-B, low-density lipoprotein cholesterol and the long-term risk of coronary heart disease in men. Am J Cardiol. 2006- 97 (7): 997- 1001.
- St-Pierre AC, Cantin B, Dagenais GR, et al. LDL subfraction and the long-term risk of ischemic heart disease in men (13-year follow-up data from Quebec Cardiovascular Study). Arterioscler Tromb Vase Biol. 2005- 25: 553 9.
- Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet, 1999- 353: 118−9.
- Sudhop T, Lutjohann D, von Bergmann K. Sterol transporters: targets of natural sterols and new lipid lowering drugs. Pharmacol Ther 2005- 105: 333−41.
- Sudhop T, van Bergman K. Cholesterol absorption inhibitors for the management of hypercholesterolemia. Drugs, 2002- 4(J): 5 — 8.
- Svannborg A, Svennercholm L. Plasma total lipid cholesterol, triglycegides, phospholipids and free fatty acids in healthy Scandinavian men. Acta Med Scand, 1961, 169: 43−5.
- Talmud PJ, Hawe E, Miller GJ, et al. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Tromb Vase Biol. 2002- 22: 1918 23.
- The European Study Group. Efficacy and tolerability of Simvastatin and Pravastatin in patients with primary hypercholesterolemia (Multicountry Comparative Study). Am J Cardiol. 1992- 70: 1281 86.
- The SimvastatinEnalapril Coronary Atherosclerosis Trial Group. The Simvastatin Atgerosclerosis Trial (SCAT). Presented at the 48 Annual Scientific Session on the American College of Cardiology, march 1999.
- Toth PP, Davidson MH. Simvastatin plus ezetimibe: combination therapy for the management of dislipidaemia. Expert Opin Pharmacother. 2005- 6: 131−9.
- Turley SD. Dietary cholesterol and mechanisms of cholesterol absorption. Eur Heart J 1999- 1 (suppl.): 529−35.
- Van Heek M, Farley C, Compton DS et al. «Comparison of activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucoronude, SCH60663. British Pharmacology, 2000- 129: 1748−54.
- Vaskovsky VE, Kostetsky EY, Vasendin JM. A universal reagent for phospholipid analysis. J Chromatogr. 1975, 114: 129−41.
- Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein AI, and improvement in the prediction of fatal myocardial infarction (AMORIS study) (a prospective study). Lancet. 2001- 358: 2026 33.
- Whicher JT, Ritchie RF, Johnson AM, et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem, 1994 — 40: 934 -8.
- Zetia (ezetimibe) package insert, rev 08. Merck/Schering Plough Pharmaceuticals. Issued July 2005.
- Zhu Y, Statkevich P, Kosoglou T, et al. Effect of ezetimibe (SCH 58 235) on the activity of drug metabolizing in vivo. Clin Pharmacol Ter, 2000- 6(7): 152.
- Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation, 1979- 60 (3): 474 85.